by Raynovich Rod | Apr 3, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Caution As Life Science Stocks Are Consolidating Life science stocks had a wild roller coaster ride in 2014 with many stocks peaking around March 1. Momentum and cult stocks in our portfolio still had a good quarter with the following top winners: Illumina (ILMN) up...
by Raynovich Rod | Mar 18, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Update 3/19/14 Trading is mixed near flat line. Cramer to pump Seattle Genetics (SGEN ($53.51 flat) today; on our focus list since’09 at $9.50. Exact Sciences (EXAS) up ~3% on data release for Cologuard compared to FIT. Sensitivity of 92% with colorectal cancer...
by Raynovich Rod | Feb 3, 2014 | 2024 Rayno Tools and Diagnostics Portfolio
Molecular Diagnostics and Sequencing Technologies Are Big Winners in January 2014 But Recent Two Day Sell-Off Has Done Damage To Many Stocks Diagnostic stocks were a sea of red today after a huge January driven by growth expectations from new products and platform...
by Raynovich Rod | Jan 31, 2014 | 2024 Rayno Tools and Diagnostics Portfolio
A Few Winners on A Weak Day-IBB ($247.80) Down 1.22% Slightly Off Highs of $254. Two of Our Best DX Picks Have Been Cepheid and Illumina Cepheid (CPHD $53) up 12% on 20% Q4 Revenue Gains . Full year revenues were $401.3 with a net loss of $18M. Illumina (ILMN...
by Raynovich Rod | Jan 30, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Update 12:40p NASDAQ Up 2% Cardiovascular Sciences (CSII $33.90) Up 15 %-Beats on Revenues and EPS. Q2 Revenues up 28% to $32.3M. Net Loss was $8.7M compared to $5.8M in 2013 fiscal Q2. Thermo Fisher (TMO $114) up 2.4% on 10% 2013 EPS gain. Q4 revenues up 6% to...
by Raynovich Rod | Jan 20, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
2014 J.P. Morgan Conference Update #5-Rayno Diagnostics and Tools Portfolio Amazing start for the New Year Performance among Clinical Diagnostics and Tools stocks was strong with many stocks beating the sector indices (IBB) which were up 10-15%. Stock performance...
by Raynovich Rod | Jan 16, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Biotech Rally Continues With IBB ($245) At New Highs-Up 10 Pts. From Monday’s Bottom Several Rayno Life Science picks were up after presentations at the 2014 J.P.Morgan Healthcare Conference. All of our portfolio picks are strong holds unless otherwise noted....
by Raynovich Rod | Jan 9, 2014 | 2024 Rayno Tools and Diagnostics Portfolio
Two Rayno Laggards Up On Good Volume: RGDX, SQNM The only two losers among our portfolio picks in 2013 are up today. Response Genetics (RGDX $1.32) is up 2.56% on a volume of almost 500k shares with no apparent news. The Company raised $4.8M in December at $1.20 share...
by Raynovich Rod | Jan 7, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Update 1/8/13 Blow-Off anticipating J.P.Morgan Conference? Breakthrough: IBB hit new highs above $230 today. Green screen with most large cap and mid caps. ALKS, BIIB among movers. XBI is also up 2%. Rayno Life Science stocks are in the bullish groove as investors...
by Raynovich Rod | Dec 30, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
New Products for Molecular and Companion Diagnostics Drive Growth Rayno Life Science Big Winners-ALR, CSII, ILMN,TMO A diversified life science portfolio must include clinical diagnostics and tools stocks because of the synergies between therapy and diagnostics....
